Published in Medical Letter on the CDC and FDA, August 30th, 2009
"To assess the safety and efficacy of conivaptan for the treatment of euvolemic hyponatremia in the neurocritical care unit. Data were obtained retrospectively on 22 patients treated with conivaptan for euvolemic hyponatremia. End points evaluated included time to [Na]...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA